Breast Cancer: Current Research
天美传媒 Access
Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 天美传媒 Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
天美传媒 Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 114
Indexed In
- RefSeek
- Hamdard University
- EBSCO A-Z
- Publons
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Evaluation of diffusion weighted MR Imaging and 18F-FDG PET for monitoring triple negative breast cancer response to cisplatin treatment
5th World Congress on Breast Cancer
Nguyen Thu Huong, Hirofumi Hanaoka, Takahito Nakajima and Yoshito Tsushima
Gunma University Graduate School of Medicine, Japan Bach Mai hospital, Vietnam
ScientificTracks Abstracts: Breast Can Curr Res
DOI:
Abstract
Objective: To evaluate the potential of 18F-FDG PET and diffusion weighted MR Imaging (DWI) in predicting response of triple negative breast cancer (TNBC) to Cisplatin treatment. Methods: Cisplatin (10 mg/kg) was injected one shot intraperitoneally into TNBC tumor bearing mice. Animals were imaged on PET and MRI scanners dedicated to animal use before treatment (day 0) and days 3 and 7 after treatment. The highest standardized uptake value (SUVmax) and the average of apparent diffusion coefficient value (ADCmean) were measured. Results: We evaluated tumor growth of the non-treated mice (n=8) and treatment mice. Treated mice were divided into the response group (n=7) and the no response group (n=7) based on whether the tumor growth was similar to or slower than that of the non-treated mouse. SUVmax value on day 3 and day 7 (SUV3, SUV7) showed significant difference between the response group and no response group (P<0.05), however, ratio of SUVmax on day 7 to day 0 (SUV7/0) showed no significant difference between three groups (P>0.05). ADC mean value on day 0 (ADC0) of the response group was significantly lower than that of the no response group (P<0.01). The ratio of ADC mean on day 7 to day 0 (ADC7/0) showed significant difference between three groups (P<0.01), and ADC7/0 of the response group were significantly higher than those of control group and no response group. Conclusions: ADC0, ADC7/0 is potential early predictors of response of TNBC to cisplatin treatment.Biography
MD radiologist in Bach Mai hospital of Vietnam, PhD student in Gunma University of Japan .
Email: sundayntxq@gmail.com
